Tango Therapeutics shares surge 11.38% after-hours after hitting 52-week high and analysts raise price targets to $14–$15.

Tango Therapeutics (TNGX) surged 11.38% in after-hours trading following a combination of bullish catalysts. The stock reached a 52-week high of $12.67, reflecting a 320.5% annual return and a $1.69 billion market cap, driven by strong analyst sentiment, including a "Strong Buy" consensus and a $15 price target from Stifel. Piper Sandler also raised its price target to $14 from $11, citing vopimetostat’s potential as a best-in-class PRMT5 inhibitor. Leadership changes, including the appointment of Malte Peters as CEO and Sung Lee to the board, further bolstered investor confidence. Despite the stock trading above fair value and projected losses, the positive momentum was reinforced by advancements in clinical programs and a $100 million at-the-market equity offering, which underscored the company’s strategic flexibility and market optimism.